Instrument Inactif

Communiqués MOUN CRES Nasdaq

Actions

MCADU

US62402D2045

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	19/09/22	PU
MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	16/09/22	PU
MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	14/09/22	PU
MOUN CRES : Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K	11/08/22	PU
MOUN CRES : Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results - Form 8-K	28/07/22	PU
MOUN CRES : Statement of Changes in Beneficial Ownership (Form 4)	07/07/22	PU
MOUN CRES : Better Therapeutics Appoints Frank Karbe as Chief Executive Officer - Form 8-K	07/06/22	PU
MOUN CRES : Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results - Form 8-K	28/03/22	PU
MOUN CRES : KOL Call Discussing Better Tx's Top Line Results for BT-001 283.3 KB	22/03/22	PU
MOUN CRES : MARCH 15, 2022 Primary Endpoint Day 90 Analysis Better+ THERAPEUTICS - Form 8-K/A	15/03/22	PU
MOUN CRES : Better Therapeutics Announces Positive Primary Endpoint Data from Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients with Uncontrolled Type 2 Diabetes - Form 8-K	15/03/22	PU
MOUN CRES : Amendment to Current Report (Form 8-K/A)	14/01/22	PU
Employee Spotlight: Michelle Gearhart	16/12/21	PU
MOUN CRES : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Form 8-K/A	26/11/21	PU
MOUN CRES : Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes - Form 8-K	18/11/21	PU
MOUN CRES : Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors - Form 8-K	17/11/21	PU
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Form 8-K	03/11/21	PU
BETTER THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Change in Shell Company Status, Financial Statements and Exhibits (form 8-K)	03/11/21	AQ
Mass General Brigham Joins Better Therapeutics in Real World Evidence Study Collaboration	02/11/21	BU
Better Therapeutics Closes Business Combination and Debuts on Nasdaq	29/10/21	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués MOUN CRES Nasdaq

Actions

MCADU

US62402D2045

Communiqués

Filtres